Tatro Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Tatro Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$449K	Buy	+4,990	New	+$461K	0.34%	48

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Tatro Capital's XBI Position: Q1 2022 in Review

Tatro Capital opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2022: 4,990 shares worth $449K. The stake represents 0.34% of the portfolio and ranks #48 among its holdings.

702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Tatro Capital held 4,990 shares of State Street SPDR S&P Biotech ETF worth $449K as of Q1 2022.
State Street SPDR S&P Biotech ETF was a new Tatro Capital position in Q1 2022.
State Street SPDR S&P Biotech ETF made up 0.34% of Tatro Capital's portfolio in Q1 2022, its #48 holding.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Tatro Capital's 13F filing for Q1 2022, filed 13 May 2022.